---
title: "2 consecutive trading limits for YODON: The company does not have any violations of fair information disclosure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/232546621.md"
description: "YODON announced an abnormal fluctuation in stock trading, stating that the company's current production and operation situation is normal, and there have been no significant changes in the internal and external operating environment. After self-examination, the company confirms that there are no violations of information fair disclosure. The pre-disclosure date for the company's 2024 annual report is April 9, 2025, and there are no circumstances requiring the disclosure of performance forecasts; the undisclosed 2024 performance information has not been provided to any third party other than the accounting firm auditing the company"
datetime: "2025-03-20T08:52:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/232546621.md)
  - [en](https://longbridge.com/en/news/232546621.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/232546621.md)
generator: "portal-rs"
---

# 2 consecutive trading limits for YODON: The company does not have any violations of fair information disclosure

On March 20th, Jinshi Data reported that YODON announced an abnormal fluctuation in stock trading, stating that the company's current production and operation situation is normal, and there have been no significant changes in the internal and external operating environment. After self-examination, the company confirmed that there are no violations of information fair disclosure. The pre-disclosure date for the company's 2024 annual report is April 9, 2025, and there is no need to disclose performance forecasts; there is no situation where undisclosed 2024 performance information has been provided to any third party other than the accounting firm auditing the company

### Related Stocks

- [002406.CN](https://longbridge.com/en/quote/002406.CN.md)

## Related News & Research

- [08:27 ETHyGen Promotes Omid Ghobadi to Chief Operating Officer](https://longbridge.com/en/news/297786116.md)
- [Huber+Suhner (SWX:HUBN) Confirms 2026 Margin View On An Undervalued Narrative](https://longbridge.com/en/news/297431768.md)
- [ZAWYA: Bahrain: LuLu set to invest $165mln in six new outlets](https://longbridge.com/en/news/297868851.md)
- [Knight Therapeutics wins Colombia approval for Tavalisse in chronic ITP](https://longbridge.com/en/news/297703037.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**